Chronic Leukemias and Lymphomas

Biology, Pathophysiology, and Clinical Management

  • Gary J. Schiller

Part of the Current Clinical Oncology book series (CCO)

Table of contents

  1. Front Matter
    Pages i-ix
  2. Kanti R. Rai, Niraj Gupta
    Pages 1-21
  3. Jamie D. Cavenagh, T. Andrew Lister
    Pages 23-53
  4. Nicole Wentworth, Alan Saven
    Pages 55-78
  5. Peter J. Rosen, Jonathan Said
    Pages 79-92
  6. Neil P. Shah, Charles L. Sawyers
    Pages 93-114
  7. Lauren C. Pinter-Brown
    Pages 115-151
  8. Mustafa Benekli, Maria R. Baer
    Pages 153-183
  9. Nelida N. Sjak-Shie, Gary J. Schiller
    Pages 185-213
  10. James R. Berenson, Robert A. Vescio
    Pages 215-248
  11. Christos Emmanouilides
    Pages 249-276
  12. R. Gregory Bociek, James O. Armitage
    Pages 277-298
  13. Steven M. Horwitz, Sandra J. Horning
    Pages 299-327
  14. Back Matter
    Pages 329-342

About this book


In the last decade advances in basic and clinical research on chronic leukemias and lymphomas-slowly progressive diseases of the blood and bone marrow-have produced a host of remarkable therapies, including the use of unique small molecules targeted at specific genetic lesions: pro-apoptotic drugs, monoclonal antibodies, and adoptive immunotherapy. In Chronic Leukemias and Lymphomas: Biology, Pathophysiology, and Clinical Management, a panel of recognized experts in hematological oncology describe the unique biological features of indolent hematologic neoplasms, providing powerful insight into their clinical manifestation, highlighting potential targets for novel therapies, and distinguishing these disorders from aggressive lymphoma and Hodgkin's disease. In their integrated surveys of chronic myeloproliferative and lymphoproliferative disorders, the authors place special emphasis on such unique entities as prolymphocytic leukemias and cutaneous lymphomas. Among the disease models considered for chronic lymphocytic leukemia, low-grade lymphoma, and chronic myelogenous leukemia are impairments of the apoptotic mechanisms, as well as specific molecular events that initiate proliferation. Both models of oncogenesis may lead to novel therapeutic targets, such as purine nucleoside analogs for chronic lymphocytic leukemias, monoclonal antibodies for follicular lymphomas, and STI-571 (Gleevec) for chronic myelogenous leukemia.
Comprehensive and up-to-date, Chronic Leukemias and Lymphomas: Biology, Pathophysiology, and Clinical Management is a unique book devoted to summarizing both the basic biology and the practical management of myeloproliferative disorders, low grade lymphomas, and chronic leukemias, distinguishing these disorders from large-cell lymphoma and Hodgkin's disease. Special emphasis is given to the mechanisms of disease progression with authoritative insights into the promising new era of antineoplastic pharmacology.


Staging biology cell leukemia lymphoma oncology pathophysiology pharmacology physiology

Editors and affiliations

  • Gary J. Schiller
    • 1
  1. 1.Division of Hematology-OncologyUCLA School of MedicineLos AngelesUSA

Bibliographic information